ORKA

Business Context and Reporting Period

This summary covers the Form 10-Q for ARCA biopharma, Inc. (trading symbol: ABIO) for the quarterly period ended June 30, 2024. Although the request metadata mentions "Oruka Therapeutics, Inc.," the filing is for ARCA, which is currently in the process of merging with Oruka. ARCA is a clinical-stage biopharmaceutical company focused on precision medicine for cardiovascular diseases, with lead candidates Gencaro (for atrial fibrillation) and rNAPc2 (for COVID-19). The company is a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: The company has no revenue and has incurred substantial losses since inception. There is no debt on the balance sheet; liabilities consist primarily of accounts payable and accrued expenses.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the six months ended June 30, 2024, was $4.7 million, compared to $2.8 million for the same period in 2023. This increase is primarily driven by higher General and Administrative (G&A) expenses.
• G&A Expense Surge: G&A expenses rose to $5.3 million for the six months ended June 30, 2024, from $3.1 million in the prior year. This $2.2 million increase is attributed to approximately $2.0 million in professional fees related to the proposed Merger with Oruka and $0.2 million in one-time termination benefits for the former CEO.
• Decreased R&D Expenses: Research and Development expenses decreased to $0.3 million for the six months ended June 30, 2024, from $0.6 million in the prior year. This reduction is due to decreased headcount and the cessation of unrestricted research grants with the former CEO's academic laboratory.
• Interest Income: Interest and other income remained relatively stable at $0.9 million for the six months ended June 30, 2024, compared to $0.9 million in the prior year, benefiting from higher interest rates.
• Cash Position: Cash and cash equivalents decreased by $4.1 million to $33.3 million as of June 30, 2024, reflecting the net cash used in operating activities.

Guidance, Outlook, and Material Events

Merger with Oruka Therapeutics

On April 3, 2024, ARCA entered into a definitive Merger Agreement with Oruka Therapeutics, Inc. The transaction involves a reverse merger where Oruka will become a wholly-owned subsidiary of ARCA. Key terms include:

• Ownership Structure: Pre-merger Oruka stockholders are expected to own approximately 97.61% of the combined company, while pre-merger ARCA stockholders will own approximately 2.39%.
• Financing: Oruka has secured a subscription agreement for approximately $275.0 million in PIPE financing, contingent on the merger closing.
• Special Dividend: ARCA expects to declare a special cash dividend to pre-merger stockholders equal to the amount by which ARCA's net cash exceeds $5.0 million at closing (estimated at approximately $20.0 million).
• Asset Disposal: ARCA will dispose of its legacy technology and IP (Gencaro and rNAPc2) contingent on stockholder approval, effectively making ARCA a shell company prior to the merger.

Liquidity and Going Concern

Management believes current cash resources ($33.3 million) are sufficient to fund operations through the end of fiscal year 2025. However, future viability beyond that point depends on the successful consummation of the Merger or the ability to raise additional capital. The company explicitly states that if the Merger is not completed, it may explore dissolution and liquidation.

Risks and Contingencies

• Legal Proceedings: A stockholder lawsuit (Wynter v. ARCA biopharma, Inc.) was filed on May 20, 2024, alleging the preliminary registration statement for the merger was misleading. ARCA intends to defend vigorously.
• Merger Uncertainty: The transaction is subject to numerous closing conditions, including stockholder approvals, Nasdaq listing approval, and regulatory clearances. Failure to close could lead to liquidation.
• Executive Changes: Dr. Michael Bristow resigned as CEO and Director effective April 3, 2024. Thomas A. Keuer was appointed President and Principal Executive Officer.

Investor Verification Checklist

• Merger Approval Status: Verify the status of stockholder votes required for both ARCA and Oruka to approve the Merger Agreement.
• Special Dividend Calculation: Confirm the final net cash position at closing to determine the exact amount of the special cash dividend payable to ARCA shareholders.
• Legal Litigation: Monitor the outcome of the Wynter lawsuit, as an injunction could delay or prevent the merger.
• PIPE Financing Closing: Confirm that the $275 million financing transaction for Oruka has been executed and funds are secured.
• Asset Disposal: Verify the terms and timing of the disposal of ARCA's legacy assets (Gencaro and rNAPc2) to ensure they are transferred as part of the merger consideration or sold separately.
• Nasdaq Listing: Confirm that the combined entity meets Nasdaq listing requirements, particularly regarding the reverse stock split and minimum bid price.